Fingerprint
Dive into the research topics of 'RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically